Analytical Data
-
Gene name
Efhd2
- Application
-
Alternative Names
Swiprosin-1
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9D8Y0
-
Expression Region
2-240aa
-
Molecular Weight
42.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EFHD2 (E-FHAND domain-containing protein 2) is a member of the EF-hand family of proteins, known for their role in calcium ion binding and signaling. Research into EFHD2 has gained traction due to its implicated roles in muscle function, signal transduction, and potential involvement in various pathological conditions, including neurodegenerative diseases and cancers. Characterization of EFHD2 and its recombinant protein forms is critical for understanding its biological functions and mechanisms. Previous studies have suggested that EFHD2 may participate in cytoskeletal regulation and cellular motility, impacting processes such as differentiation and apoptosis. The recombinant expression of EFHD2 provides a powerful tool for elucidating its functional domains, interaction partners, and cellular pathways. Continued exploration of EFHD2 could yield insights into its therapeutic potential, particularly in conditions where calcium homeostasis and cellular communication are disrupted. Advances in recombinant protein techniques and structural biology are paving the way for detailed studies of EFHD2, enriching our comprehension of this protein's role in health and disease.
